Diabetic-retinopathy concerns with GLP-1 agonists allayed

More risk with insulin therapy study suggests

Contrary to previous reports, glucagon-like receptor-1(GLP-1) agonists do not appear to increase patients' risk of diabetic retinopathy, according to research based on UK data.

"Overall, the results of our large population-based study are reassuring with respect to the retinal safety of GLP-1 receptor agonists," Dr Antonios Douros from Jewish General Hospital and McGill University, in Montreal, Canada, said by email.

"Previous concerns over a possible association of these drugs with an increased risk of diabetic retinopathy could not be corroborated in a real-world